Incontinence Clinical Trial
Official title:
Current Perception Threshold Testing for Sacral Neuuromodulation Outcomes
This is a prospective study. Subjects will be recruited from the urology practices of Dr.
Ken Peters and Dr. Ananias Diokno at William Beaumont Hospital. Subjects will be referred to
the study by the clinician recommending Sacral NeuroModulation therapy (SNM).
This pilot study is to explore the effect of SNM on sensory pathways by measuring CPT values
pre and post SNM treatment.
Patients will be scheduled 1-2 weeks prior to planned implantation of the SNM wire electrode
(Stage 1). Patients that do not have a 50% improvement in their symptoms in Stage 1 will not
go on to Stage II procedures and will not undergo further CPT testing.
After enrollment, the subjects will complete a short medical history questionnaire
confirming that they meet inclusion criteria and do not fall under exclusion criteria. This
will include review of recent urinalysis and/or urine culture confirming the absence of a
recent urinary tract infection. Participants will be given information on the relevant CPT
testing including the need for bladder/urethra catheterization as part of that testing pre
and post SNM therapy.
At the baseline testing visit, subjects will undergo CPT testing using transcutaneous
stimulation in the distribution of the pudendal nerve on the perineum. Subjects will undergo
bladder/urethral catheterization in using standard sterile technique. Once the
bladder/urethral catheter is in place CPT testing will be conducted at various frequencies
of to identify the current perception thresholds of each nerve fiber.
At the conclusion of the testing the catheter will be removed and the subjects will be given
a single dose of an oral antibiotic to minimize infection. This meeting and testing will
require approximately 60 minutes.
Patients will undergo Stage I of the SNM procedure with their own physician at a subsequent
appointment.
If subjects have a 50% improvement in their symptoms after 2 weeks with Stage 1 SNM, they
will under go Stage II of the SNM procedure.
The subjects will have an appointment scheduled for their follow-up CPT testing at the
clinical research office 4 to 6 weeks after the Stage II procedure. The subject will be
given a urinalysis and urine culture lab slip, and will be instructed to drop a urine sample
off at the lab 3 days before their scheduled appointment for testing. If their urine culture
is positive, they will be given a prescription for an antibiotic and excluded from this
testing. They may however be tested once their urine culture is negative, as long as it is
within 2 weeks of their original post-stage 2 CPT test appointment
Subjects will undergo repeat CPT testing using transcutaneous stimulation in the
distribution of the pudendal nerve on the perineum. Subjects will then undergo
bladder/urethral catheterization using standard sterile technique. Once the bladder/urethral
catheter is in place CPT testing will then be conducted at various frequencies to identify
the current perception thresholds of each nerve fiber.
At the conclusion of the testing the catheter will be removed and the patients will be given
a single dose of an oral antibiotic to minimize infection. This evaluation will require
approximately 60 minutes.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Completed |
NCT01978210 -
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
|
N/A | |
Completed |
NCT00972998 -
Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01036035 -
Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04110821 -
Quality of Life After Conservative and Surgical Treatment of Pelvic Organ Prolapse
|
||
Recruiting |
NCT05826691 -
Benign Prostate Surgery and QOL and Sexual Function
|
||
Recruiting |
NCT05362292 -
TReating Incontinence for Underlying Mental and Physical Health
|
Phase 4 | |
Recruiting |
NCT05935371 -
Consequences of Obstetric Anal Sphincter Injuries on Maternal Psychology and Relationship Experience
|
||
Completed |
NCT02554201 -
Efficacy of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
Completed |
NCT01486706 -
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
|
Phase 2/Phase 3 | |
Completed |
NCT02633592 -
Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry
|
N/A | |
Completed |
NCT01747343 -
Toilet Training Toddlers and Preschoolers
|
N/A | |
Completed |
NCT01470001 -
The Effect of Solifenacin on Post Void Dribbling in Women
|
N/A | |
Recruiting |
NCT02091947 -
Efficacy of Functional Magnetic Stimulation in Urinary Incontinence
|
Phase 2 | |
Completed |
NCT01108367 -
Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate (HoLEP)
|
N/A | |
Completed |
NCT04924218 -
Evaluation of the Effect of Endoscopic Urethral Procedures Applied After Radical Prostatectomy on Urinary Incontinence
|
N/A | |
Recruiting |
NCT04010292 -
Enhancing Patient Recall in Urogynecologic Surgery
|
N/A | |
Completed |
NCT05106010 -
The Effect of Yoga on Decreasing Risk of Fall-Related Injury in Peri and Post-Menopausal
|
||
Completed |
NCT04867876 -
Qol Following Management for Pediatric UI
|
N/A |